Key Points
- Illumina director Keith Meister sold 62,691 shares at an average $215.48, worth about $13.51 million, reducing his position by 16.93% to 307,659 shares.
- The company reported quarterly EPS of $1.62, above the $1.36 consensus, and revenue of $1.17 billion, ahead of estimates and up 4.2% year over year.
- Analysts’ average rating was Hold, with an average price target of $244.24; the stock was reported down 1.6%.
Illumina, Inc. (NASDAQ:ILMN - Get Free Report) Director Keith Meister sold 62,691 shares of the stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $215.48, for a total transaction of $13,508,656.68. Following the completion of the sale, the director owned 307,659 shares of the company's stock, valued at approximately $66,294,361.32. The trade was a 16.93% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Illumina Trading Down 1.6%
Shares of ILMN opened at $209.55 on Friday. Illumina, Inc. has a 12-month low of $112.65 and a 12-month high of $309.35. The company has a quick ratio of 2.05, a current ratio of 2.63 and a debt-to-equity ratio of 0.57. The firm has a market capitalization of $31.68 billion, a price-to-earnings ratio of 40.56, a P/E/G ratio of 2.89 and a beta of 1.46. The stock's 50-day moving average price is $249.32 and its 200 day moving average price is $179.36.
Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The life sciences company reported $1.62 EPS for the quarter, beating the consensus estimate of $1.36 by $0.26. Illumina had a return on equity of 28.38% and a net margin of 19.72%. The firm had revenue of $1.17 billion during the quarter, compared to analysts' expectations of $1.15 billion. During the same quarter in the prior year, the firm posted $1.34 EPS. The company's revenue for the quarter was up 4.2% on a year-over-year basis. As a group, research analysts predict that Illumina, Inc. will post 5.43 earnings per share for the current year.
Recent Illumina Headlines
Here are a few of the latest headlines about ILMN:
- Positive Sentiment: Illumina reported third-quarter revenue of $1.129 billion and net income of $220 million, raised its 2026 revenue outlook to $4.64 billion–$4.66 billion, and highlighted strength in clinical sequencing consumables. How Investors May Respond To Illumina (ILMN) Earnings Beat
- Positive Sentiment: The company expanded its molecular residual disease research portfolio with an ultrasensitive duplex sequencing workflow for circulating tumor DNA and was selected to provide whole-genome sequencing services for Singapore’s SG-INSIGHT precision-medicine study. These developments support its push into clinical oncology and sequencing applications. Illumina (ILMN) Unveils Duplex Sequencing Workflow For MRD Research
- Negative Sentiment: Director Keith Meister sold 280,091 shares over November 9–11 for approximately $61.1 million, reducing his direct holdings to 208,826 shares. The scale of the sales could raise concerns among investors, despite his continuing substantial ownership. SEC filing
Analysts Set New Price Targets
A number of research analysts recently commented on ILMN shares. Guggenheim upped their target price on Illumina from $226.00 to $305.00 and gave the company a "buy" rating in a research note on Thursday, October 1st. Weiss Ratings upgraded shares of Illumina from a "hold (c)" rating to a "buy (b-)" rating in a research note on Monday, November 2nd. Wall Street Zen downgraded shares of Illumina from a "buy" rating to a "hold" rating in a research note on Saturday, November 7th. Barclays boosted their price target on shares of Illumina from $160.00 to $200.00 and gave the company an "underweight" rating in a report on Wednesday, October 7th. Finally, Citigroup increased their price objective on shares of Illumina from $113.00 to $210.00 and gave the company a "sell" rating in a research note on Monday, November 2nd. Ten analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, Illumina has an average rating of "Hold" and an average target price of $244.24.
Get Our Latest Research Report on Illumina
Institutional Investors Weigh In On Illumina
A number of institutional investors have recently added to or reduced their stakes in the stock. Baker Tilly Wealth Management LLC grew its stake in shares of Illumina by 3.3% in the 3rd quarter. Baker Tilly Wealth Management LLC now owns 1,297 shares of the life sciences company's stock valued at $355,000 after purchasing an additional 42 shares during the period. Ashton Thomas Securities LLC raised its holdings in shares of Illumina by 3.3% in the 3rd quarter. Ashton Thomas Securities LLC now owns 1,348 shares of the life sciences company's stock worth $369,000 after buying an additional 43 shares in the last quarter. Elevation Wealth Partners LLC raised its holdings in shares of Illumina by 19.7% in the 3rd quarter. Elevation Wealth Partners LLC now owns 292 shares of the life sciences company's stock worth $80,000 after buying an additional 48 shares in the last quarter. Evergreen Capital Management LLC raised its holdings in shares of Illumina by 0.5% in the 3rd quarter. Evergreen Capital Management LLC now owns 9,474 shares of the life sciences company's stock worth $2,593,000 after buying an additional 50 shares in the last quarter. Finally, Pinnacle Associates Ltd. lifted its position in shares of Illumina by 2.2% during the 3rd quarter. Pinnacle Associates Ltd. now owns 2,506 shares of the life sciences company's stock worth $686,000 after buying an additional 54 shares during the period. 89.42% of the stock is owned by institutional investors and hedge funds.
Illumina Company Profile
(
Get Free Report)
Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company's technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
